Quick Answer
Barinthus Biotherapeutics plc. reported Revenue From Contract With Customer Excluding Assessed Tax of $0.00 for the year ending 2025.
- Barinthus Biotherapeutics plc. showed a decrease of -100.0% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from Barinthus Biotherapeutics plc.'s annual report (Form 10-K), filed with the SEC on March 13, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 6 years of available data (2020 to 2025), Barinthus Biotherapeutics plc.'s Revenue From Contract With Customer Excluding Assessed Tax has declined by 100.0%.
- Historical annual values: Fiscal year 2025: $0.00 | Fiscal year 2024: $14.97 million | Fiscal year 2023: $802.0 thousand | Fiscal year 2022: $44.70 million | Fiscal year 2021: $268.0 thousand | Fiscal year 2020: $4.82 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: